Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“First ever dual payload ADC in the clinic by Chengdu Kanghong Biotech! KH815, a dual-payload ADC targeting TROP2.
Payloads:
“Drug-T” and “Drug-E”
And one of the two payloads is definitely a topoisomerase I inhibitor.”
“First-In-Human Study in Participants with Advanced Solid Tumors”